SS-31

Clinical Trials

Elamipretide (MTP-131)

Aliases
Elamipretide, MTP-131, Bendavia
Administration
Subcutaneous injection, IV infusion (clinical)

Timing

A general projection of what people report noticing over time, based on the known mechanism and reported use patterns. It is not a guarantee and individual experience varies considerably.

  1. 1

    1–2 Weeks

    Effects are generally described as subtle, if present, given the compound's cellular-level mechanism.

  2. 2

    3–4 Weeks

    Some users report modestly steadier energy or reduced fatigue during exertion.

  3. 3

    5–7 Weeks

    Continued use may bring further subtle improvements in exercise tolerance for some.

  4. 4

    8–10 Weeks

    Effects, where reported, tend to build gradually rather than suddenly.

  5. 5

    11–15 Weeks

    Long-term users often describe a background sense of improved stamina rather than a distinct sensation.

  6. 6

    16–20 Weeks

    Continued observation is generally needed to notice meaningful trends.

  7. 7

    21–24 Weeks

    By this stage, users typically evaluate whether measurable markers support continued use.

⚠️ Research context only. This is not medical advice and results are not guaranteed.